As Pfizer Inc. continues to grow its oncology business, it's pushing both new molecules and expanding the indications of its approved drugs.
Andy Schmeltz, global president of Pfizer Oncology, described the company's strategy as a three-pronged approach at a May 15 press...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

